Understand the source comparison
Cartalax Peptide vs Cartalax: Comparison
Before purchasing, researchers often compare products labelled differently to determine if formulation or quality differences justify price variations. The following table clarifies what actually differs between products labelled 'Cartalax peptide' and 'Cartal
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before purchasing, researchers often compare products labelled differently to determine if formulation or quality differences justify price variations. The following table clarifies what actually differs between products labelled 'Cartalax peptide' and 'Cartalax'.
- Amino Acid Sequence
- Ala-Glu-Asp (tripeptide)
- No. Identical molecular structure
- Molecular Weight
- ~305.24 g/mol
- No. Same compound
- Synthesis Method
- Solid-phase peptide synthesis (SPPS)
- No. Standard synthesis pathway
- Target Tissue Selectivity
- Cartilage, connective tissue
- No. Same bioregulatory target
- Typical Purity Range
- ≥98% by HPLC
- No. Purity standards are identical
- Reconstitution Protocol
- Bacteriostatic water, 2–8°C storage
- No. Handling requirements identical
- Research Application Scope
- Joint tissue studies, cartilage repair models, aging research
- No. Experimental use cases overlap completely
- Naming Convention Origin
- Western biochemical nomenclature (adds 'peptide' for clarity)
- Original Russian Institute naming (short form)
- Yes. But only affects catalogue search terms, not the compound itself
- The bottom line: if two suppliers both deliver Ala-Glu-Asp at verified purity with proper lyophilisation and cold-chain shipping, the name on the label ('Cartalax peptide' versus 'Cartalax') is irrelevant to research outcomes. Sequence fidelity, purity verification, and handling integrity determine experimental reliability. Not nomenclature.